Notice is hereby given that a securities fraud class action lawsuit has been filed on behalf of those who purchased or otherwise acquired ACADIA Pharmaceuticals Inc. ("ACADIA") (Nasdaq:  ACAD) securities between April 29, 2016 and July 9, 2018, both dates inclusive (the "Class Period").

The complaint alleges that throughout the Class Period, the defendants failed to disclose that:  (1) adverse events and safety concerns related to NUPLAZID threatened the drug’s initial and continuing FDA approval; (2) ACADIA engaged in business practices likely to attract regulatory scrutiny; and (3) as a result of the foregoing, the defendants’ statements about ACADIA’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

ACADIA investors may receive additional information about the case by filling out the form on this page.